A randomised evaluation of <scp>low‐dose</scp> cytosine arabinoside plus lenalidomide versus <scp>single‐agent low‐dose</scp> cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the <scp>LI</scp>‐1 trial-Reference-Cited by-同舟云学术

A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI‐1 trial

Published:2023-11-28 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Copland Mhairi¹^ORCID,Ariti Cono²³,Thomas Ian F.²,Upton Laura²,Sydenham Mia²,Mehta Priyanka⁴^ORCID,Islam Shahid⁵,Kjeldsen Lars⁶,Burnett Alan K.¹,Hills Robert K.⁷^ORCID,Russell Nigel⁸^ORCID,Dennis Mike⁹^ORCID,

Affiliation:

1. Paul O'Gorman Leukaemia Research Centre, School of Cancer Sciences University of Glasgow Glasgow UK

2. Centre for Trials Research Cardiff University Cardiff UK

3. Oxon Epidemiology Madrid Spain

4. University Hospitals of Bristol and Weston NHS Trust Bristol UK

5. Department of Haematology Waikato Hospital Hamilton New Zealand

6. Rigshospitalet Copenhagen University Hospital Copenhagen Denmark

7. Nuffield Department of Population Health University of Oxford Oxford UK

8. Guy's and St Thomas' NHS Trust London UK

9. The Christie Manchester UK

Abstract

SummaryImproving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI‐1 trial, we evaluated lenalidomide (LEN) in combination with low‐dose cytosine arabinoside (LDAC) in patients aged >60 years unfit for intensive therapy and compared this to LDAC alone. Two hundred and two patients, randomised 1:1, were evaluable. Overall response rate (CR + CRi) was higher for LDAC + LEN versus LDAC (26% and 13.7% respectively p = 0.031). However, there was no difference in overall survival between the arms (14% and 11.5% at 2 years for LDAC + LEN and LDAC respectively). The addition of LEN was associated with increased toxicity and supportive care requirements.

Funder

Blood Cancer UK

Celgene

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19220

Reference14 articles.

1. Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper

2. Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis

3. An evaluation of 17 years of low dose cytarabine as therapy for AML patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy;Dennis M;Blood,2017

4. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

5. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial